Where does Aerie Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Aerie Pharmaceuticals, Inc. ranks #7,106 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Aerie Pharmaceuticals, Inc. hold?

Aerie Pharmaceuticals, Inc. holds 46 US utility patents granted between 2015 and 2024, spanning 9 technology areas.

What is Aerie Pharmaceuticals, Inc.'s Innovation Score?

Aerie Pharmaceuticals, Inc. has an Innovation Score of 38.8 out of 100 (top 40% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Aerie Pharmaceuticals, Inc. focus on?

Aerie Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 41 patents, ranking #446 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Aerie Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Aerie Pharmaceuticals, Inc.'s recent grant velocity is +71% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Aerie Pharmaceuticals, Inc.'s patents?

Aerie Pharmaceuticals, Inc.'s patents average 19.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Aerie Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Aerie Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 46 granted patents across 9 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Aerie ranks #7,106 of 49,997 tracked US assignees by granted-patent volume, with 46 patents across 9 technology areas.

#7,106
of 49,997 US assignees by volume: Top 40%
by Innovation Score (38.8/100): 19.8
avg claims per patent: +71%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7106 · US Corporation #7,106 · 46 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 46 grants
UPPER-Q #7,106/49,997
PHOTO-FINISH Ankon Medical…
CPC-NARROW A61P · 9 areas
INNOV-THIN 38.8/100
CLAIMS-RICH 19.8 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +71% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ankon Medical Technologies (SHANGHAI) Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Aerie’s 38.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.3 pts (34%) Velocity 3.0 pts (8%) Breadth 10.6 pts (27%) Claim depth 11.9 pts (31%)

Qualcomm Incorporated · highest

85
4D Pharma Research · near

39
Aerie Pharmaceuticals · this assignee

39
DPG USA · near

39
Oy Halton Group · near

39
Webroot · near

39
3D Lighting… · lowest

7

What this shows Aerie's Innovation Score is 38.8/100 (top 40% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Aerie?

Each dot is one of Aerie’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aerie’s own 19.8 claims/patent is ABOVE the 16.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Aerie vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Aerie's grants concentrate

Aerie Pharmaceuticals, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 89.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (10 grants) versus a trough of 1 in 2015. By volume, Aerie sits between Ankon Medical Technologies (SHANGHAI) Co., Ltd. and Auspex Pharmaceuticals, Inc..

Aerie's three-year grant acceleration

From 2019–2021 to 2022–2024, Aerie Pharmaceuticals, Inc. moved from 22 to 10 grants (0.46x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Ankon Medical (Sh…

46
Applied Invention

46
Ariel Scientific…

46
Atonarp

46
Anton Paar

46
Araxes Pharma

46
Artisan Vehicle S…

46
Auspex Pharmaceut…

46
Aerie Pharmaceuti… ◀

46

What this shows Aerie holds 46 patents at rank #7,113, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Aerie

By rank, the assignees closest to #7,113 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Aerie's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Aerie, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Aerie ranks #446 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

4D Pharma Research Limited 39 Oy Halton Group Ltd. 39 Webroot Inc. 39 DPG USA Inc. 39

Aerie's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Aerie Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	2.2%
2016	3	6.5%
2017	3	6.5%
2018	7	15.2%
2019	3	6.5%
2020	9	19.6%
2021	10	21.7%
2022	3	6.5%
2023	5	10.9%
2024	2	4.3%

Which technologies does Aerie Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 41

C07D - Heterocyclic Compounds 39

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

C07C - Acyclic OR Carbocyclic Compounds 19

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 3

C07J - Steroids 2

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

A61B - DIAGNOSIS; SURGERY; Identification 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Aerie Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Aerie Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 89.1% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #7,106 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Aerie Pharmaceuticals, Inc. against Ankon Medical Technologies (SHANGHAI) Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.